HOME >> BIOLOGY >> NEWS
Allelix drug increases bone density and content in women with osteoporosis

SAN FRANCISCO, Dec. 3, 1998 -- Allelix Biopharmaceuticals (TSE/ME: AXB) announced today results of a Phase II clinical trial demonstrating that its compound ALX1-11, recombinant human parathyroid hormone significantly increases bone mineral density (BMD) and bone mineral content (BMC) in the spine of women with postmenopausal osteoporosis.

Dr. Robert Lindsay, president of the National Osteoporosis Foundation today reported the results from the double blind, placebo controlled, clinical trial of the drug at the American Society for Bone and Mineral Research (ASBMR) meeting.

"ALX1-11 appears to be a promising novel approach to treat the millions of people with osteoporosis especially that which affects the spine," said Dr. Lindsay, one of the study's principal investigators, who holds the position of professor of clinical medicine at Columbia University School of Medicine. "These data are particularly encouraging because patients at the higher dose had greater increases in bone mass than have been observed with currently available therapies. For the many patients with more advanced osteoporosis, this rapid increase in bone mass and density could be an important clinical benefit."

"These results confirm that ALX1-11 can rapidly increase bone mass and produce new bone," said Dr. John Dietrich, senior vice president of research and development at Allelix. "We believe that ALX1-11 will offer osteoporosis patients an important new option to decrease their risk of experiencing incapacitating fractures."

The Phase II trial was conducted in 18 centers in the United States and Canada and involved 217 women with postmenopausal osteoporosis. The women, who ranged in age from 50-75, gave themselves daily subcutaneous injections of ALX1-11 for one year. The women received one of three doses of the drug or a placebo, for comparison. In addition, to the Allelix drug, all of the women rece
'"/>

Contact: Maria Tenaglia
m.tenaglia@noonanrusso.com
212-696-4455 ext 216
Noonan/Russo Communications
3-Dec-1998


Page: 1 2 3 4

Related biology news :

1. Allelix Clones Receptor For Intestinal Growth Factor GLP-2
2. USC study links historical increases in life span to lower childhood exposure to infection
3. Moderate alcohol consumption increases plasma levels of a protective hormone
4. Protease-inhibitor cocktail protects, increases anti-microbial action of promising new peptide
5. Breast self examination increases womens concerns but has no effect on mortality
6. Educational program increases some safety behaviors for older drivers
7. Placental malaria increases mother-to-child HIV transmission
8. NIEHS-funded researchers find low-level ozone increases respiratory risk of asthmatic children
9. Northwesterns Cancer Genetics Program pinpoints gene that increases cancer risk by 26 percent
10. Common gene variant increases risk of atherosclerosis
11. Prenatal exposure to nicotine increases risk of apnea in brains of newborn rats

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... ... 17, 2020 , ... Commercial launch readiness is a critical stage in a ... cure or vaccine, the global economic downturn will only increase price pressures overall for ... and capturing full value from every product launch is critical. However, history shows that ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. ... Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at ... Paul J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label ...
(Date:6/28/2020)... Switzerland (PRWEB) , ... June ... ... provider of enterprise software solutions for biopharmaceutical R&D, today announced that it ... company developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... ... biotechnology, and diagnostics companies, has announced the placement of Julianne Averill , ... responsible for leading all financial operations and implementing key business strategies to accelerate ...
(Date:8/15/2020)... ... August 13, 2020 , ... True Terpenes , ... of its Scientific Advisory Board (SAB) to research the medical potential of terpenes and ... enhanced when combined with terpenes. The board is focused on expanding the recently launched ...
(Date:8/12/2020)... ... 2020 , ... The FSHD Society announced today that it ... Trial Research Network (FSHD CTRN), with consideration of follow-on funding of $300,000 ... research centers in the United States and Europe with expertise in FSHD clinical ...
(Date:8/12/2020)... BINGHAM FARMS, Mich. (PRWEB) , ... August 12, ... ... International Consulting Group, Inc. (EMMA International), a global leader in FDA compliance ... ranking of the nation’s fastest-growing private companies. The list represents a unique look ...
Breaking Biology Technology:
Cached News: